236 related articles for article (PubMed ID: 18582952)
1. Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis.
Jones MV; Nguyen TT; Deboy CA; Griffin JW; Whartenby KA; Kerr DA; Calabresi PA
J Neuroimmunol; 2008 Aug; 199(1-2):83-93. PubMed ID: 18582952
[TBL] [Abstract][Full Text] [Related]
2. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.
Zagon IS; Rahn KA; Bonneau RH; Turel AP; McLaughlin PJ
Brain Res; 2010 Jan; 1310():154-61. PubMed ID: 19931226
[TBL] [Abstract][Full Text] [Related]
3. T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/6 x SJL) F1 mice.
Zhang GX; Yu S; Gran B; Li J; Calida D; Ventura E; Chen X; Rostami A
J Neuroimmunol; 2004 Mar; 148(1-2):1-10. PubMed ID: 14975581
[TBL] [Abstract][Full Text] [Related]
4. Spinal cord histopathology of MOG peptide 35-55-induced experimental autoimmune encephalomyelitis is time- and score-dependent.
Recks MS; Addicks K; Kuerten S
Neurosci Lett; 2011 May; 494(3):227-31. PubMed ID: 21406210
[TBL] [Abstract][Full Text] [Related]
5. Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE).
Olechowski CJ; Truong JJ; Kerr BJ
Pain; 2009 Jan; 141(1-2):156-64. PubMed ID: 19084337
[TBL] [Abstract][Full Text] [Related]
6. An MHC anchor-substituted analog of myelin oligodendrocyte glycoprotein 35-55 induces IFN-gamma and autoantibodies in the absence of experimental autoimmune encephalomyelitis and optic neuritis.
Ford ML; Evavold BD
Eur J Immunol; 2004 Feb; 34(2):388-97. PubMed ID: 14768043
[TBL] [Abstract][Full Text] [Related]
7. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE).
Musgrave T; Benson C; Wong G; Browne I; Tenorio G; Rauw G; Baker GB; Kerr BJ
Brain Behav Immun; 2011 Nov; 25(8):1677-88. PubMed ID: 21723939
[TBL] [Abstract][Full Text] [Related]
8. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis.
Brown DA; Sawchenko PE
J Comp Neurol; 2007 May; 502(2):236-60. PubMed ID: 17348011
[TBL] [Abstract][Full Text] [Related]
9. Decreased neural stem/progenitor cell proliferation in mice with chronic/nonremitting experimental autoimmune encephalomyelitis.
Guo J; Li H; Yu C; Liu F; Meng Y; Gong W; Yang H; Shen X; Ju G; Li Z; Wang J
Neurosignals; 2010; 18(1):1-8. PubMed ID: 19786810
[TBL] [Abstract][Full Text] [Related]
10. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Roscoe WA; Welsh ME; Carter DE; Karlik SJ
J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
[TBL] [Abstract][Full Text] [Related]
11. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
[TBL] [Abstract][Full Text] [Related]
12. A novel protective model against experimental allergic encephalomyelitis in mice expressing a transgenic TCR-specific for myelin oligodendrocyte glycoprotein.
Mendel I; Natarajan K; Ben-Nun A; Shevach EM
J Neuroimmunol; 2004 Apr; 149(1-2):10-21. PubMed ID: 15020060
[TBL] [Abstract][Full Text] [Related]
13. CD62L is required for the priming of encephalitogenic T cells but does not play a major role in the effector phase of experimental autoimmune encephalomyelitis.
Li O; Liu JQ; Zhang H; Zheng P; Liu Y; Bai XF
Scand J Immunol; 2006 Aug; 64(2):117-24. PubMed ID: 16867156
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of CNTF in Mesenchymal Stem Cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice.
Lu Z; Hu X; Zhu C; Wang D; Zheng X; Liu Q
J Neuroimmunol; 2009 Jan; 206(1-2):58-69. PubMed ID: 19081144
[TBL] [Abstract][Full Text] [Related]
15. Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.
Campbell AM; Zagon IS; McLaughlin PJ
Brain Res; 2012 Sep; 1472():138-48. PubMed ID: 22820301
[TBL] [Abstract][Full Text] [Related]
16. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis.
Gresle MM; Shaw G; Jarrott B; Alexandrou EN; Friedhuber A; Kilpatrick TJ; Butzkueven H
J Neurosci Res; 2008 Dec; 86(16):3548-55. PubMed ID: 18709652
[TBL] [Abstract][Full Text] [Related]
17. A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation.
Fu YF; Zhu YN; Ni J; Zhong XG; Tang W; Re YD; Shi LP; Wan J; Yang YF; Yuan C; Nan FJ; Lawson BR; Zuo JP
J Pharmacol Exp Ther; 2006 Nov; 319(2):799-808. PubMed ID: 16914558
[TBL] [Abstract][Full Text] [Related]
18. Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis.
Pifarre P; Prado J; Baltrons MA; Giralt M; Gabarro P; Feinstein DL; Hidalgo J; Garcia A
Acta Neuropathol; 2011 Apr; 121(4):499-508. PubMed ID: 21234581
[TBL] [Abstract][Full Text] [Related]
19. Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis.
Chan J; Ban EJ; Chun KH; Wang S; McQualter J; Bernard C; Toh BH; Alderuccio F
Autoimmunity; 2008 Aug; 41(5):405-13. PubMed ID: 18568646
[TBL] [Abstract][Full Text] [Related]
20. Soluble egg antigen from Schistosoma japonicum modulates the progression of chronic progressive experimental autoimmune encephalomyelitis via Th2-shift response.
Zheng X; Hu X; Zhou G; Lu Z; Qiu W; Bao J; Dai Y
J Neuroimmunol; 2008 Feb; 194(1-2):107-14. PubMed ID: 18207251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
